Series A Fundraising

Case Study: Series A Fundraising

Why PharmaVentures?

PharmaVentures was chosen because of its expertise in valuation, partnering and fundraising and its network of key decision makers within major investment institutions with whom they are in regular dialogue with.

This mixture of skills and connections positioned PharmaVentures to translate technical, scientific value into a commercial proposition and then negotiate the investment to completion, deriving optimal value for the client from their fundraising transaction.

The Series A Fundraising Challenge

 

Biosceptre wanted to carry out a series A fundraising to allow them to advance their three oncology clinical assets which were BIL010t, a polyclonal antibody ointment for the topical treatment of non-melanoma skin cancers, BIL06v, a peptide protein  conjugate and BIL03s, fully human domain monoclonal, both for systemic uses targeting solid and blood cancers.

 

The Solution

Initially, PharmaVentures conducted an independent valuation for Biosceptre’s developmental assets. Following this, PharmaVentures was appointed to partner its preclinical and early clinical asset portfolio, and/or to raise capital.

PharmaVentures deployed a dual-track process, during which we:​

  • Provided our expert opinion on optimal deal structures​
  • Developed a compelling “investment story” for each of the audience group (strategic partners vs financial investors)​
  • Connected the client with key decision makers in each target company​
  • Managed the BD&L process, including marketing, developing relationships with potential investors and partners, and negotiation support.​

A Series A investment was successfully closed, whereby a Chinese VC group Tuspark invested in Biosceptre.

Commercialisation Strategy

Case Study: Commercialisation Strategy

The Commercialisation Strategy Challenge

An early stage biotechnology company was seeking to develop a global/regional strategy for the commercialisation of their Phase I compound to maximise the value to the company over the potential life cycle of the product.

The Solution

PharmaVentures conducted a detailed assessment of the market opportunities, technology risks and developments, launch and marketing costs via scenarios of “go-it-alone”, “outright sale”, “out-licensing for royalties” as well as “out-licensing with co-promotion”.

The value generated was modelled and the scenarios were prioritised. Partnering and deal strategies were developed for the selected optimal strategy and incorporated into a business plan.

Pharmaceutical Company Growth

Case Study: Pharmaceutical Company Growth

Why PharmaVentures?

PharmaVentures was chosen because its knowledge of the global pharmaceutical market, access to proprietary data resources as well its transaction experience in effectively acquiring these on behalf of clients.

The Challenge

A major pharmaceutical company was seeking mid market growth products for emerging markets.

The Solution

PharmaVentures developed a customised search strategy based on the specific requirements of the client, which involved a systemic country by country identification of candidates with the correct therapeutic indications, combined with their commercial potential and availability for the territories of interest. These prospects were delivered to the client on a rolling weekly basis, with an initial data pack, with sufficient information to allow the client to select leads. For each lead Pharmaventures generated a tailored proposal which was the basis of formal and confidential approach by PharmaVentures on behalf of our client to capture the business opportunity.

This project has identified many more promising leads than the client had been able to achieve with its own resources and PharmaVentures has contributed to an efficient acquisition process.

European Biotech Licensing Transactions

Case Study: European Biotech Licensing Transactions

Why PharmaVentures?

PharmaVentures was chosen because its experience in valuing clinical development assets, marketing these and supporting the negotiations leading up to the closure of licensing deals.

The Biotech Licensing Challenge

A European biotech needed to licence a clinical phase compound to treat a CNS disease.

The Solution

PharmaVentures conducted a compound valuation (bottom-up and bench marking using PharmaDeals Agreement s® data) providing the basis for future negotiations. PharmaVentures also carried out a thorough company screening and evaluation assessment to identify and prioritise potential licensees. Following the screening, within the space of a month PharmaVentures’ transaction team approached all the target companies with a carefully constructed value proposition using a non-confidential information package.

PharmaVentures managed the exchange of Confidential Disclosure Agreements followed by the facilitation of meetings leading to the exchange of confidential data presentations. PharmaVentures also set up and managed a confidential data room.

Dow Chemical

Case Study: Dow Chemical

Why PharmaVentures?

Dow chose PharmaVentures because its track record in conducting auctions for pharmaceutical assets, completing sales in a timely manner and returning maximum value to its clients.

The Challenge

The Dow Chemical Company (Dow) engaged PharmaVentures to generate a transaction process and close a deal with the highest bidder for the opportunity.

The Solution

PharmaVentures conducted a thorough company screening and evaluation assessment to identify and prioritise potential acquirers with a good match for the technology and a strong strategic need in the relevant therapy area. Following the screening, within the space of a month PharmaVentures’ transaction team approached all the target companies with the value proposition using a non-confidential information package.

PharmaVentures managed the exchange of Confidential Disclosure Agreements followed by providing confidential information in a memorandum, supporting management presentations and managed access to the dataroom. Finally PharmaVentures provided negotiations support leading to the sale of Dow’s API manufacturing assets to Dr Reddy’s Laboratories.